|
⚲
|
| China Yongxin Pharmaceuticals Inc | |
|---|---|
| Firm | |
| Fund # | |
| CIK # | 0001087848 |
| Sale | 2010-01-25 ($1.5 M Offered, $0.9 M Sold) |
| Fund | |
| Phone | 6265819098 |
| Address | 927 Canada Ct City of Industry, 91748 |
| Source | [EDGAR] |
| Fund AUM and Sold ($k) |
|---|
| Fund Details | |
|---|---|
| Director | |
| Custodian | |
| Auditor | |
| Marketer | |
| Broker | |
| Jurisdiction |
| Directors | 2011 - 2025 |
|---|---|
| Umesh Patel | |
| Harry Zhang | |
| Yongkui Liu | |
| Yongmei Wang | |
| Ning Liu | |
| Corp Streetcapital | |
| Yongxin Liu |
| Comparable Firms | State | AUM ($B) |
|---|---|---|
|
Cancer Targeting Systems, Inc.
✚
|
0.0 | |
|
ATeams, Inc.
✚
|
0.0 | |
|
ATS 218, a series of SAX Capital Series Fund III, LP
✚
|
0.0 | |
|
AU Fund I, a series of 5 Eyes Ventures, LP
✚
|
0.0 | |
|
AU Fund I, a series of Matt Bilotti AL Funds, LP
✚
|
0.0 | |
|
AU Fund I, a series of Ride Wave Ventures, LP
✚
|
0.0 | |
|
SAB IV Financial Industries Partnership L.P.
✚
|
0.0 | |
|
Diameter Credit (BDC) Access LP
✚
|
0.0 | |
|
Diamondback Acquisition, Inc.
✚
|
0.0 | |
|
Canamed, Inc.
✚
|
0.0 |